Information about the ongoing exercise period for TO3.
April 11 – April 25 2019 is exercise period of Brighter TO3 during which holders of the warrants can subscribe for shares. One (1) TO3 can be exchanged for one (1) share during the period, at a price of SEK 4.
Holders of warrants who have their warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner if they want to exercise the warrants and subscribe for the corresponding shares.
Exercise of the warrants and subscription of shares for other holders of warrants takes place through simultaneous payment and submittal of the registered application form (link), signed and submitted to the Company’s share agent (Eminova Fondkommission) no later than 16:00 CET on April 25, 2019.
In case of need of further assistance or questions, please contact the company’s share agent Eminova Fondkommission by phone 08-684 211 00 or by email info@eminova.se.
The two final TO3 exercise periods are:
- 11 October 2019 up until 25 October 2019
- 10 April 2020 up until 24 April 2020
For terms and conditions of the Warrants, please visit: https://brighter.se/investors/financing
About Brighter AB.
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare’s biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their relatives, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. https://brighter.se/
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se.